Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

References for PMC Articles for PubMed (Select 21106779)

1.

Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues.

Shelburne CP, Nakano H, St John AL, Chan C, McLachlan JB, Gunn MD, Staats HF, Abraham SN.

Cell Host Microbe. 2009 Oct 22;6(4):331-42. doi: 10.1016/j.chom.2009.09.004.

2.

Partial protection against Helicobacter pylori in the absence of mast cells in mice.

Ding H, Nedrud JG, Wershil B, Redline RW, Blanchard TG, Czinn SJ.

Infect Immun. 2009 Dec;77(12):5543-50. doi: 10.1128/IAI.00532-09. Epub 2009 Oct 12.

3.

Interleukin-15 mediates potent antiviral responses via an interferon-dependent mechanism.

Foong YY, Jans DA, Rolph MS, Gahan ME, Mahalingam S.

Virology. 2009 Oct 25;393(2):228-37. doi: 10.1016/j.virol.2009.07.030. Epub 2009 Sep 3.

4.

Comparison of monkeypox viruses pathogenesis in mice by in vivo imaging.

Osorio JE, Iams KP, Meteyer CU, Rocke TE.

PLoS One. 2009 Aug 11;4(8):e6592. doi: 10.1371/journal.pone.0006592.

5.

Progressive vaccinia in a military smallpox vaccinee - United States, 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):532-6.

6.

Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum.

Kawakami Y, Tomimori Y, Yumoto K, Hasegawa S, Ando T, Tagaya Y, Crotty S, Kawakami T.

J Exp Med. 2009 Jun 8;206(6):1219-25. doi: 10.1084/jem.20082835. Epub 2009 May 25.

7.

Vaccinia-induced epidermal growth factor receptor-MEK signalling and the anti-apoptotic protein F1L synergize to suppress cell death during infection.

Postigo A, Martin MC, Dodding MP, Way M.

Cell Microbiol. 2009 Aug;11(8):1208-18. doi: 10.1111/j.1462-5822.2009.01327.x. Epub 2009 Apr 22.

8.

Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.

Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, Erez N, Orr N, Reuveny S, Ordentlich A, Laub O, Shafferman A, Velan B.

Vaccine. 2009 Mar 10;27(11):1691-9. doi: 10.1016/j.vaccine.2009.01.038. Epub 2009 Feb 3.

PMID:
19195492
9.

Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.

Satheshkumar PS, Anton LC, Sanz P, Moss B.

J Virol. 2009 Mar;83(6):2469-79. doi: 10.1128/JVI.01986-08. Epub 2009 Jan 7.

10.

Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.

Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, Koriazova L, Kubo R, Kato S, Crotty S.

J Virol. 2009 Feb;83(3):1201-15. doi: 10.1128/JVI.01797-08. Epub 2008 Nov 19.

11.

Severe eczema vaccinatum in a household contact of a smallpox vaccinee.

Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL, Gerber SI, Garcia-Houchins S, Lederman E, Hruby D, Collins L, Scott D, Thompson K, Barson JV, Regnery R, Hughes C, Daum RS, Li Y, Zhao H, Smith S, Braden Z, Karem K, Olson V, Davidson W, Trindade G, Bolken T, Jordan R, Tien D, Marcinak J.

Clin Infect Dis. 2008 May 15;46(10):1555-61. doi: 10.1086/587668.

12.

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

Xiao Y, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, Davis HL, Braciale TJ, Eisenberg RJ, Cohen GH, Isaacs SN.

Vaccine. 2007 Jan 26;25(7):1214-24. Epub 2006 Oct 17.

13.

Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.

Shearer JD, Siemann L, Gerkovich M, House RV.

Antimicrob Agents Chemother. 2005 Jul;49(7):2634-41.

14.

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.

Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G.

Nat Med. 2005 Jul;11(7):740-7. Epub 2005 Jun 12.

PMID:
15951823
15.

An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model.

Law M, Pütz MM, Smith GL.

J Gen Virol. 2005 Apr;86(Pt 4):991-1000.

16.

Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice.

Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW.

J Infect Dis. 2004 Sep 15;190(6):1132-9. Epub 2004 Aug 3.

17.

Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells.

Gerber A, Heimburg A, Reisenauer A, Wille A, Welte T, Bühling F.

Eur Respir J. 2004 Jul;24(1):40-8.

18.

Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.

Quenelle DC, Collins DJ, Kern ER.

Antiviral Res. 2004 Jul;63(1):33-40.

PMID:
15196818
19.

Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.

Neyts J, Leyssen P, Verbeken E, De Clercq E.

Antimicrob Agents Chemother. 2004 Jun;48(6):2267-73.

20.

Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER.

Antimicrob Agents Chemother. 2004 Feb;48(2):404-12. Erratum in: Antimicrob Agents Chemother. 2004 May;48(5):1919.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk